145.53
price down icon0.32%   -0.47
after-market アフターアワーズ: 148.45 2.92 +2.01%
loading
前日終値:
$146.00
開ける:
$144.56
24時間の取引高:
1.08M
Relative Volume:
0.94
時価総額:
$14.79B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
22.37
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+2.99%
1か月 パフォーマンス:
+3.62%
6か月 パフォーマンス:
+13.59%
1年 パフォーマンス:
-1.26%
1日の値動き範囲:
Value
$143.00
$145.98
1週間の範囲:
Value
$140.75
$146.59
52週間の値動き範囲:
Value
$122.14
$186.12

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1052)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
145.53 14.79B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
20.15 64.37B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
39.97 46.62B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.00 43.98B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
77.80 32.15B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
586.48 25.15B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-06 再開されました Guggenheim Buy
2026-06-02 再開されました Goldman Buy
2026-05-22 開始されました Bernstein Outperform
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
09:51 AM

Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill

09:51 AM
pulisher
Oct 27, 2026

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research

Oct 27, 2026
pulisher
Oct 27, 2026

Healthcare stocks with strong revenue growth and attractive valuations - TradingView

Oct 27, 2026
pulisher
Oct 26, 2026

Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope - Finviz

Oct 26, 2026
pulisher
Oct 26, 2026

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia - PR Newswire

Oct 26, 2026
pulisher
Oct 26, 2026

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research

Oct 26, 2026
pulisher
Oct 26, 2026

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 26, 2026
pulisher
Oct 25, 2026

Where Will Neurocrine Biosciences Be in 5 Years? - Yahoo Finance

Oct 25, 2026
pulisher
Oct 25, 2026

Where Will Neurocrine Biosciences Be in 5 Years? - The Motley Fool

Oct 25, 2026
pulisher
Oct 23, 2026

Neurocrine Biosciences, Inc. Estimates – NASDAQ:NBIX - TradingView

Oct 23, 2026
pulisher
Oct 22, 2026

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome - PR Newswire

Oct 22, 2026
pulisher
Oct 21, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK

Oct 21, 2026
pulisher
Oct 21, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance

Oct 21, 2026
pulisher
Oct 20, 2026

Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Underv - GuruFocus

Oct 20, 2026
pulisher
Oct 20, 2026

Neurocrine Biosciences starts Alzheimer's Phase 2 trial - Mugglehead Investment Magazine

Oct 20, 2026
pulisher
Oct 20, 2026

Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease - Yahoo Finance

Oct 20, 2026
pulisher
Oct 20, 2026

Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment - Pluang

Oct 20, 2026
pulisher
Oct 20, 2026

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease - TradingView

Oct 20, 2026
pulisher
Oct 20, 2026

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease - PR Newswire

Oct 20, 2026
pulisher
Oct 19, 2026

Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating - Yahoo Finance

Oct 19, 2026
pulisher
Oct 17, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia

Oct 17, 2026
pulisher
Oct 17, 2026

How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street

Oct 17, 2026
pulisher
Oct 17, 2026

How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street

Oct 17, 2026
pulisher
Oct 16, 2026

Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings - Yahoo Finance

Oct 16, 2026
pulisher
Oct 16, 2026

Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks? - Simply Wall Street

Oct 16, 2026
pulisher
Oct 16, 2026

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia - PR Newswire

Oct 16, 2026
pulisher
Oct 16, 2026

Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target - TradingView

Oct 16, 2026
pulisher
Oct 15, 2026

RBC keeps USD 187.00 target for Neurocrine Biosciences stock - ad-hoc-news.de

Oct 15, 2026
pulisher
Oct 15, 2026

JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) - Stock Titan

Oct 15, 2026
pulisher
Oct 15, 2026

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.

Oct 15, 2026
pulisher
Oct 15, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada

Oct 15, 2026
pulisher
Oct 14, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

Non-operating income (total) of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView

Oct 14, 2026
pulisher
Oct 14, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK

Oct 14, 2026
pulisher
Oct 14, 2026

TD Cowen reiterates Neurocrine Bio stock rating on growth outlook - Investing.com

Oct 14, 2026
pulisher
Oct 14, 2026

TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com - Investing.com India

Oct 14, 2026
pulisher
Oct 14, 2026

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 13, 2026

This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's

Oct 13, 2026
pulisher
Oct 13, 2026

Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued - GuruFocus

Oct 13, 2026
pulisher
Oct 13, 2026

Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore

Oct 13, 2026
pulisher
Oct 13, 2026

Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – FWB:NB3 - TradingView

Oct 13, 2026
pulisher
Oct 13, 2026

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 12, 2026

BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $150 - Moomoo

Oct 12, 2026
pulisher
Oct 12, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Porterville Recorder

Oct 12, 2026
pulisher
Oct 12, 2026

Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan

Oct 12, 2026
pulisher
Oct 12, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Arizona Daily Star

Oct 12, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Neurocrine Biosciences Inc (NBIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
DAVID WARREN BOYER
Officer
Sep 14 '26
Proposed Sale
156.22
4,714
736,421
0
MATTHEW C ABERNETHY
Officer
Sep 14 '26
Proposed Sale
156.22
2,311
361,024
0
ABERNETHY MATT
Chief Financial Officer
Sep 14 '26
Sale
157.20
2,311
363,285
42,808
ERIC BENEVICH
Officer
Sep 09 '26
Proposed Sale
155.13
2,154
334,150
0
BENEVICH ERIC
Chief Commercial Officer
Sep 09 '26
Sale
154.61
2,154
333,030
64,408
BENEVICH ERIC
Chief Commercial Officer
Sep 09 '26
Option Exercise
43.24
3,194
138,109
66,562
Norwalk Leslie V
Director
Jul 29 '26
Option Exercise
139.43
842
117,400
2,430
Norwalk Leslie V
Director
Jul 28 '26
Sale
182.01
1,250
227,508
1,588
INGRID DELAET
Officer
Jul 10 '26
Proposed Sale
180.55
4,367
788,462
0
Delaet Ingrid
Chief Regulatory Officer
Jul 10 '26
Option Exercise
106.02
4,367
462,989
20,592
RDY RDY
$14.15
price up icon 2.91%
$22.65
price up icon 0.00%
$18.77
price up icon 0.27%
$45.25
price up icon 2.10%
$95.18
price up icon 6.70%
$21.14
price down icon 1.40%
大文字化:     |  ボリューム (24 時間):